Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3999 - Advanced acinic cell carcinoma harbors kinase rearrangements including BRAF kinase domain duplications


09 Oct 2016


Poster display


Siraj Ali


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


S.M. Ali1, K. Fedorchak2, A.B. Schrock3, J. Johnson4, K. Gowen2, J.A. Elvin5, J. Vergilio5, S.J. Klempner6, R. Mehra7, A. Ho8, D. Pavlick2, J. Suh5, R. Bordoni9, D.H. Jung10, P. Stephens2, C.H. Chung11, J.S. Ross12, V. Miller13

Author affiliations

  • 1 Research And Development, Foundation Medicine, Inc, 02141 - Cambridge/US
  • 2 Research And Development, Foundation Medicine, Inc, Cambridge/US
  • 3 Clinical Development, Foundation Medicine, Inc., Cambridge/US
  • 4 Medical Oncology, Kimmel Cancer Center-Thomas Jefferson University, Philadelphia/US
  • 5 Pathology, Foundation Medicine, Inc., 02141 - Cambridge/US
  • 6 Medical Oncology, The Angeles Clinic and Research Institute, 90025 - Los Angeles/US
  • 7 Oncology, Fox Chase Cancer Center, Philadelphia/US
  • 8 Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US
  • 9 Medical Oncology, Georgia Cancer Specialists, marietta/US
  • 10 Otolarynology, Mass Eye and Ear Infirmary, Boston/US
  • 11 Medical Oncology, H. Lee Moffitt Cancer Center University of South Florida, Tampa/US
  • 12 Pathology, Albany Medical Center, 12208 - Albany/US
  • 13 Clinical Development, Foundation Medicine, Inc., 02141 - Cambridge/US


Abstract 3999


A subset of patients with acinic cell carcinoma (AcCC), a typically indolent tumor arising from the exocrine cells of salivary glands, will experience substantial morbidity and mortality from recurrent and metastatic disease. No consensus guidelines exist for management of advanced AcCC.


72 advanced AcCC cases were assayed with hybrid-capture based comprehensive genomic profiling (CGP) in the course of clinical care to identify genomic alterations (GA) suggesting benefit from targeted therapy.


61 (85%) of AcCC had at least one GA (mean 2.1 GA per case), and clinically relevant genomic alterations (CRGA) were identified in 27 (38%) AcCC cases. The genes most commonly altered were CDKN2A (60%), PTEN (8%), and TP53 (7%). Other genes altered at 4% or less included FBXW7, ATM1, NF1 and BRAF. GAs affecting the PI3K/AKT/mTOR pathway (PTEN, PIK3CA, FBXW7) were present in 15% of cases, and no other signaling pathways were repeatedly perturbed. Of three BRAF altered cases (4%), one harbored a V600E mutation and two harbored BRAF kinase domain duplications (KDD), with one of the latter patients having a >6 month dramatic response to the promiscuous RAF inhibitor regorafenib. Three cases (4%), all of parotid origin, harbored ETV6-NTRK3 fusions. One patient responded to entrectinib (Drillon et al 2016), and another has been enrolled in a trial for investigational inhibitor.


Advanced AcCC is the first tumor type to be identified as harboring recurrent BRAF KDD, which is associated with clinical benefit from regorafenib. Moreover, detection of ETV6-NTRK3 in these cases is widely interpreted as a diagnostic of mammary analogue secretory carcinoma (MASC) with such patients predicted to benefit from NTRK inhibitors. Further investigations including RNA-sequencing are underway to define additional targetable oncogenic drivers in advanced AcCC cases not harboring the above alterations.

Clinical trial identification

Legal entity responsible for the study

Siraj Ali




S.M. Ali, K. Fedorchak, A.B. Schrock, K. Gowen, J.A. Elvin, J-A. Vergilio, D. Pavlick, J. Suh, P. Stephens, J.S. Ross, V. Miller: Employee of and equity interest in foundation medicine inc. S.J. Klempner: Speakers bureau for foundation medicine inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings